SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor

Sakamoto, Luis Henrique Toshihiro; Andrade, Rosângela Vieira de; Felipe, Maria Sueli Soares; Motoyama, Andrea Barretto; Pittella-Silva, Fabio

Registro completo de metadados

Campo DC	Valor	Idioma
dc.contributor.author	Sakamoto, Luis Henrique Toshihiro	-
dc.contributor.author	Andrade, Rosângela Vieira de	-
dc.contributor.author	Felipe, Maria Sueli Soares	-
dc.contributor.author	Motoyama, Andrea Barretto	-
dc.contributor.author	Pittella-Silva, Fabio	-
dc.date.accessioned	2022-10-06T13:08:29Z	-
dc.date.available	2022-10-06T13:08:29Z	-
dc.date.issued	2014-04	-
dc.identifier.citation	SAKAMOTO, Luis Henrique Toshihiro et al. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leukemia Research, v. 38, n. 4, p. 496-502, abr. 2014. DOI: https://doi.org/10.1016/j.leukres.2014.01.013.	pt_BR
dc.identifier.uri	https://repositorio.unb.br/handle/10482/45003	-
dc.language.iso	Inglês	pt_BR
dc.publisher	Elsevier	pt_BR
dc.rights	Acesso Restrito	pt_BR
dc.title	SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor	pt_BR
dc.type	Artigo	pt_BR
dc.subject.keyword	Proteínas	pt_BR
dc.subject.keyword	Leucemia linfoblástica aguda (LLA)	pt_BR
dc.subject.keyword	Infância	pt_BR
dc.subject.keyword	Prognóstico	pt_BR
dc.subject.keyword	Lisina	pt_BR
dc.subject.keyword	Metiltransferase	pt_BR
dc.subject.keyword	Expressão gênica	pt_BR
dc.identifier.doi	https://doi.org/10.1016/j.leukres.2014.01.013	pt_BR
dc.relation.publisherversion	https://www.sciencedirect.com/science/article/pii/S0145212614000319?via%3Dihub	pt_BR
dc.description.abstract1	Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. In this study, we performed quantitative real time PCR to compare the expression of SMYD2 in 83 pediatric ALL patients and non-neoplastic bone marrow samples (BMS). The study revealed that SMYD2 expression is altered in ALL BMS and its high expression was correlated with a bad prognosis. Moreover, we also revealed that SMYD2 expression level significantly decreases in patients that respond to chemotherapy treatment.	pt_BR
dc.contributor.affiliation	Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Patologia Molecular do Câncer	pt_BR
dc.contributor.affiliation	Universidade Católica de Brasília, Laboratório de Ciências Genômicas e Biotecnologia Molecular	pt_BR
dc.contributor.affiliation	Universidade de Brasília, Departamento de Biologia Celular	pt_BR
dc.contributor.affiliation	Hospital Infantil José Alencar de Brasília	pt_BR
Aparece nas coleções:	Artigos publicados em periódicos e afins UnB - Professores Eméritos